scholarly journals PND9 Effects and Cost of Gastrodin Injection on Dizziness and Vertigo: A Propensity Score-Matched Cohort Study Based on Real-World DATA

2020 ◽  
Vol 22 ◽  
pp. S76
Author(s):  
Y. Lai ◽  
H. Shi ◽  
W. Li ◽  
H. Zhu ◽  
R. Wang ◽  
...  
Keyword(s):  
Cohort Study ◽  
Propensity Score ◽  
Real World ◽  
Matched Cohort ◽  
Real World Data ◽  
World Data ◽  
Matched Cohort Study

scholarly journals Real world effects of COPD medications: a cohort study with validation against RCT results

2020 ◽  
pp. 2001586
Author(s):  
Kevin Wing ◽  
Elizabeth Williamson ◽  
James R Carpenter ◽  
Lesley Wise ◽  
Sebastian Schneeweiss ◽  
...  
Keyword(s):  
Cohort Study ◽  
Propensity Score ◽  
Drug Treatment ◽  
Real World ◽  
Treatment Effects ◽  
Control Group ◽  
Real World Data ◽  
Exacerbation Rate ◽  
Active Comparator ◽  
World Data

Real-world data provide the potential for generating evidence on drug treatment effects in groups excluded from trials, but rigorous, validated methodology for doing so is lacking. We investigated whether non-interventional methods applied to real-world data could reproduce results from the landmark TORCH COPD trial.We performed a historical cohort study (2000–2017) of COPD drug treatment effects in the UK Clinical Practice Research Datalink (CPRD). Two control groups were selected from CPRD by applying TORCH inclusion/exclusion criteria and 1:1 matching to TORCH participants: control group 1- people with COPD not prescribed fluticasone propionate-salmeterol (FP-SAL), control group 2- people with COPD prescribed salmeterol (SAL). FP-SAL exposed groups were then selected from CPRD by propensity-score matching to each control group. Outcomes studied were COPD exacerbations, death from any cause and pneumonia.2652 FP-SAL exposed people were propensity-score matched to 2652 FP-SAL unexposed people while 991 FP-SAL exposed people were propensity-score matched to 991 SAL exposed people. Exacerbation rate ratio was comparable to TORCH for FP-SAL versus SAL (0.85, 95% CI 0.74–0.97 versus 0.88, 0.81–0.95) but not for FP-SAL versus no FP-SAL (1.30, 1.19–1.42 versus 0.75, 0.69–0.81). Active comparator results were also consistent with TORCH for mortality (hazard ratio 0.93, 0.65–1.32 versus 0.93, 0.77–1.13) and pneumonia (risk ratio 1.39, 1.04–1.87 versus 1.47, 1.25–1.73).We obtained very similar results to the TORCH trial for active comparator analyses, but were unable to reproduce placebo-controlled results. Application of these validated methods for active comparator analyses to groups excluded from RCTs provides a practical way for contributing to the evidence base and supporting COPD treatment decisions.

scholarly journals Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jacques P. Brown ◽  
Jonathan D. Adachi ◽  
Emil Schemitsch ◽  
Jean-Eric Tarride ◽  
Vivien Brown ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hip Fracture ◽  
Fragility Fracture ◽  
Mortality Risk ◽  
Real World ◽  
First Year ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Fracture Cohort ◽  
One Year

Abstract Background Recent studies are lacking reports on mortality after non-hip fractures in adults aged > 65. Methods This retrospective, matched-cohort study used de-identified health services data from the publicly funded healthcare system in Ontario, Canada, contained in the ICES Data Repository. Patients aged 66 years and older with an index fragility fracture occurring at any osteoporotic site between 2011 and 2015 were identified from acute hospital admissions, emergency and ambulatory care using International Classification of Diseases (ICD)-10 codes and data were analyzed until 2017. Thus, follow-up ranged from 2 years to 6 years. Patients were excluded if they presented with an index fracture occurring at a non-osteoporotic fracture site, their index fracture was associated with a trauma code, or they experienced a previous fracture within 5 years prior to their index fracture. This fracture cohort was matched 1:1 to controls within a non-fracture cohort by date, sex, age, geography and comorbidities. All-cause mortality risk was assessed. Results The survival probability for up to 6 years post-fracture was significantly reduced for the fracture cohort vs matched non-fracture controls (p < 0.0001; n = 101,773 per cohort), with the sharpest decline occurring within the first-year post-fracture. Crude relative risk of mortality (95% confidence interval) within 1-year post-fracture was 2.47 (2.38–2.56) in women and 3.22 (3.06–3.40) in men. In the fracture vs non-fracture cohort, the absolute mortality risk within one year after a fragility fracture occurring at any site was 12.5% vs 5.1% in women and 19.5% vs 6.0% in men. The absolute mortality risk within one year after a fragility fracture occurring at a non-hip vs hip site was 9.4% vs 21.5% in women and 14.4% vs 32.3% in men. Conclusions In this real-world cohort aged > 65 years, a fragility fracture occurring at any site was associated with reduced survival for up to 6 years post-fracture. The greatest reduction in survival occurred within the first-year post-fracture, where mortality risk more than doubled and deaths were observed in 1 in 11 women and 1 in 7 men following a non-hip fracture and in 1 in 5 women and 1 in 3 men following a hip fracture.

ID: 3525809 COMPARATIVE OUTCOMES OF ENDOSCOPIC ERADICATION THERAPY FOR DYSPLASTIC BE USING RADIOREQUENCY ABLATION AND CRYOBALLON ABLATION: A MULTICENTER PROPENSITY SCORE MATCHED COHORT STUDY

2021 ◽  
Vol 93 (6) ◽  
pp. AB291-AB292
Author(s):  
Siddharth Agarwal ◽  
Mohammad Alshelleh ◽  
Jamie Scott ◽  
Lovekirat Dhaliwal ◽  
Don C. Codipilly ◽  
...  
Keyword(s):  
Cohort Study ◽  
Propensity Score ◽  
Eradication Therapy ◽  
Matched Cohort ◽  
Matched Cohort Study
Sign in / Sign up

Export Citation Format

Share Document